

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

**In re:**

**PURDUE PHARMA L.P., *et al.*,  
  
Debtors.<sup>1</sup>**

**Chapter 11**

**Case No. 19-23649 (RDD)**

**(Jointly Administered)**

**ORDER GRANTING THE APPLICATION OF STIKEMAN ELLIOTT LLP AS AN  
ORDINARY COURSE PROFESSIONAL FOR COMPENSATION FOR SERVICES  
RENDERED IN EXCESS OF THE TIER 1 OCP CAP FOR THE PERIOD FROM  
SEPTEMBER 1, 2021 THROUGH NOVEMBER 30, 2021**

Upon consideration of the application, by notice of presentment dated March 11, 2022 (the “**Application**”) filed by Stikeman Elliott LLP (“**Stikeman**”) pursuant to section 331 of title 11 of the United States Code (the “**Bankruptcy Code**”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”) and the *Order Authorizing Debtors to Employ Professionals Used in the Ordinary Course of Business Nunc Pro Tunc to the Petition Date* [ECF No. 548] (the “**OCP Order**”), seeking allowance of compensation for actual and necessary professional services in excess of the Tier 1 OCP Cap<sup>2</sup> in the amount of \$81,702.60 during the period of September 1, 2021 through November 30, 2021 (the “**Fee Period**”); and an

---

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

<sup>2</sup> Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the OCP Order

independent fee examiner (the “**Fee Examiner**”) having been appointed in these cases in accordance with the *Order Authorizing Appointment of Independent Fee Examiner Pursuant to 11 U.S.C. § 105(a) and Modifying Interim Compensation Procedures for Certain Professionals Employed Pursuant to 11 U.S.C. § 327* [ECF No. 1023] (the “**Fee Examiner Order**”); and the Fee Examiner having reviewed the Application in accordance with the Fee Examiner Order; and the Fee Examiner having no objection to the allowance and payment of the Applicant’s fees and expenses in the amounts set forth on Schedule A hereto; and due and proper notice of the Application and the opportunity for a hearing thereon having been provided pursuant to Bankruptcy Rules 2002(a)(6) and (c)(2) and the OCP Order; and there being no objections to the relief granted herein; and no additional notice or a hearing being required; and the Court having jurisdiction over this matter pursuant to 28 U.S.C. §§ 157(a)-(b) and 1334(b) and the Amended Standing Order of Reference M-431, dated January 31, 2012 (Preska, C.J.); and this matter being a core proceeding under 28 U.S.C. § 157(b); and venue being proper before the Court pursuant to 28 U.S.C. §§ 1408 and 1409; and it appearing that the amount set forth on **Schedule A** for which compensation is allowed hereby was actual, reasonable, and necessary; and good and sufficient cause appearing therefor,

IT IS HEREBY ORDERED THAT:

1. The Application is granted as set forth herein.
2. Stikeman is awarded interim compensation for professional services rendered during the Fee Period in excess of the Tier 1 OCP Cap in the amount set forth on **Schedule A** hereto under the column heading “Amount of Fees in Excess of Tier 1 OCP Cap Allowed.”
3. The Debtors are authorized and directed to pay Stikeman promptly the amounts of

fees approved by this Order, to the extent such amounts have not previously been paid.

4. This Court shall retain jurisdiction to hear and determine all matters arising from or related to this Order.

Dated: April 5, 2022  
White Plains, New York

*/s/Robert D. Drain*

---

HONORABLE ROBERT D. DRAIN  
UNITED STATES BANKRUPTCY JUDGE

**Schedule A**

**Application for Fees in Excess of the Tier 1 OCP Cap**

**Case No:** 19-23649 (RDD)

**Case Name:** In re Purdue Pharma L.P., *et al.*

<b>Applicant</b>	<b>Date and Docket Number of Application</b>	<b>Time Period Covered by Application</b>	<b>Amount of Fees in Excess of Tier 1 OCP Cap Requested</b>
Stikeman Elliott LLP	March 10, 2022 ECF No. 4505	9/1/2021 – 11/30/2021	\$ 81,702.60